GIKLY (GIKLY)

S&P 500 earnings roundup: big beats/misses from MSFT, AMZN, AAPL, META, QCOM, BA, XOM & more—plus next week’s key reports.

Axiom Investment Management LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 4,858 shares of the biopharmaceutical company’s stock, valued at approximately ...

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Gilead Explores Twice-Yearly HIV Regimen for Long-Term Control The Phase 3 study “A Pha...

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Gilead Sciences has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.